TY - JOUR
T1 - Impact of Late Gadolinium Enhancement on mortality, sudden death and major adverse cardiovascular events in ischemic and nonischemic cardiomyopathy
T2 - A systematic review and meta-analysis
AU - Ganesan, Anand N.
AU - Gunton, James
AU - Nucifora, Gaetano
AU - McGavigan, Andrew D.
AU - Selvanayagam, Joseph
N1 - Publisher Copyright:
© 2017
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Background: The central role of left ventricular ejection fraction (LVEF) as the definitive risk marker of adverse outcomes in ischemic and nonischemic cardiomyopathy is increasingly uncertain. The current study aimed to conduct a systematic review and meta-analysis with the objective of evaluating the prognostic importance of Late Gadolinium Enhancement (LGE) in ischemic cardiomyopathy (ICM) and non-ischemic cardiomyopathy (NICM) on the key endpoints of all-cause mortality, cardiovascular mortality and sudden death. Methods: The study was prospectively registered in PROPSERO (CRD 42016039034). Electronic databases and reference lists were searched for studies evaluating the impact of LGE-CMR on all-cause mortality, cardiovascular mortality, ventricular arrhythmia or sudden death, or major adverse cardiovascular events. Data were extracted from 36 studies including n = 7882 patients. Results: LGE was strongly associated with all-cause mortality HR 2.96 (95%CI: 2.37, 3.70, P < 0.001), cardiovascular mortality HR 3.27 (95% CI: 2.05, 5.22, P < 0.001), ventricular arrhythmia and sudden cardiac death HR 3.76 (95% CI: 3.14, 4.52, P < 0.001), and major adverse cardiovascular events HR 3.24 (95% CI: 2.32, 4.52, P < 0.001). In subgroup analyses, LGE was associated with all-cause mortality and cardiovascular mortality in both LVEF ≤ 35% and LVEF > 35% patients (P < 0.001 all endpoints), as well as in nonischemic and ischemic cardiomyopathy. Conclusion: Late Gadolinium Enhancement (LGE) in CMR predicts all-cause mortality, cardiovascular mortality, ventricular arrhythmia and sudden death, and major adverse cardiovascular events, independent of LVEF. Future trials of investigational therapies in NICM and ICM should consider the utilization of LGE to identify patients at risk of adverse outcomes.
AB - Background: The central role of left ventricular ejection fraction (LVEF) as the definitive risk marker of adverse outcomes in ischemic and nonischemic cardiomyopathy is increasingly uncertain. The current study aimed to conduct a systematic review and meta-analysis with the objective of evaluating the prognostic importance of Late Gadolinium Enhancement (LGE) in ischemic cardiomyopathy (ICM) and non-ischemic cardiomyopathy (NICM) on the key endpoints of all-cause mortality, cardiovascular mortality and sudden death. Methods: The study was prospectively registered in PROPSERO (CRD 42016039034). Electronic databases and reference lists were searched for studies evaluating the impact of LGE-CMR on all-cause mortality, cardiovascular mortality, ventricular arrhythmia or sudden death, or major adverse cardiovascular events. Data were extracted from 36 studies including n = 7882 patients. Results: LGE was strongly associated with all-cause mortality HR 2.96 (95%CI: 2.37, 3.70, P < 0.001), cardiovascular mortality HR 3.27 (95% CI: 2.05, 5.22, P < 0.001), ventricular arrhythmia and sudden cardiac death HR 3.76 (95% CI: 3.14, 4.52, P < 0.001), and major adverse cardiovascular events HR 3.24 (95% CI: 2.32, 4.52, P < 0.001). In subgroup analyses, LGE was associated with all-cause mortality and cardiovascular mortality in both LVEF ≤ 35% and LVEF > 35% patients (P < 0.001 all endpoints), as well as in nonischemic and ischemic cardiomyopathy. Conclusion: Late Gadolinium Enhancement (LGE) in CMR predicts all-cause mortality, cardiovascular mortality, ventricular arrhythmia and sudden death, and major adverse cardiovascular events, independent of LVEF. Future trials of investigational therapies in NICM and ICM should consider the utilization of LGE to identify patients at risk of adverse outcomes.
KW - Cardiovascular magnetic resonance
KW - Late Gadolinium Enhancement
KW - Meta-analysis
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85042135679&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2017.10.094
DO - 10.1016/j.ijcard.2017.10.094
M3 - Article
C2 - 29407096
AN - SCOPUS:85042135679
SN - 0167-5273
VL - 254
SP - 230
EP - 237
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -